6. Parkinson disease Clinical trials / Disease details
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03947216 (ClinicalTrials.gov) | October 23, 2020 | 7/5/2019 | Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. | Study of Pimavanserin Efficacy for the Treatment of Impulse Control Disorders in Parkinson's Disease | Parkinson Disease | Drug: Active drug: pimavanserin 17mg (2 strength tablets);Drug: Placebo: 2 tablets containing same excipients except active compound;Behavioral: Assessment of severity of ICD (impulse control disorders);Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors;Behavioral: Assessment of quality of life;Behavioral: Assessment of depression;Behavioral: Assessment of cognition;Behavioral: Assessment of severity of Parkinson Disease;Procedure: Blood analysis;Procedure: Cardiac monitoring | University Hospital, Strasbourg, France | NS-PARK;EUCLID Clinical Trial Platform;F-CRIN | Recruiting | 35 Years | 75 Years | All | 130 | Phase 2 | France |
| 2 | NCT04353947 (ClinicalTrials.gov) | March 2, 2020 | 16/4/2020 | Induction and Recognition of Emotions | Induction and Recognition of Emotions in Healthy Older Adults, Alzheimer's Disease and Parkinson's Disease | Healthy Older Adults;Alzheimer's Disease;Parkinson's Disease | Diagnostic Test: Mini Cognitive Examination (MCE);Diagnostic Test: Beck Depression Inventory-II (BDI-II);Diagnostic Test: Global Deterioration Scale (GDS);Diagnostic Test: Memory alteration test (M@T);Diagnostic Test: Spanish-Complutense Verbal Learning Test (TAVEC);Diagnostic Test: Barcelona test (BT);Diagnostic Test: Rey-Osterrieth Complex Figure Test (ROCFT);Diagnostic Test: Frontal assessment battery (FAB);Diagnostic Test: Positive and Negative Affect Scale (PANAS);Diagnostic Test: Auto-Assessment Manikins (SAM) | University of Valencia | Asociación Parkinson Valencia | Withdrawn | 65 Years | 99 Years | All | 0 | Spain | |
| 3 | NCT04477161 (ClinicalTrials.gov) | September 5, 2019 | 22/6/2020 | Effect of Ketone Esters in Parkinson's Disease | Effect of Ketone Esters on Parkinson Disease: A Pilot, Prospective Trial. | Parkinson Disease;Ketosis | Dietary Supplement: Ketone Ester Elite endurance Nutrition Drink;Other: Stool Sample | University of Florida | NULL | Completed | 40 Years | 75 Years | All | 10 | N/A | United States |
| 4 | ChiCTR1800019216 | 2017-09-30 | 2018-10-31 | Study for accurate diagnosis and treatment of Parkinson's disease by using the combination of TMS-EEG | Study for accurate diagnosis and treatment of Parkinson's disease by using the combination of TMS-EEG | Parkinson's disease | Bradykinesia Group:Sick side, SAM region, 10Hz rTMS;Tremor Group:Sick side, M1 region, 1Hz rTMS;Health control:N/A; | Shenzhen People's Hospital | NULL | Recruiting | 50 | 80 | Both | Bradykinesia Group:30;Tremor Group:30;Health control:30; | China | |
| 5 | NCT04223245 (ClinicalTrials.gov) | June 29, 2017 | 2/12/2019 | A Home Program Using Multimodal Sensory Feedback for People With Parkinson Disease | A Comparison Of Home Exercises With Multimodal Real-time Sensory Feedback To The Same Exercise Program With No Enhanced Feedback on Walking Automaticity in People With Parkinson Disease. | Parkinson Disease | Behavioral: exercise+multi-modal sensory feedback (MMSF);Behavioral: Exercise only | Regis University | NULL | Completed | 21 Years | N/A | All | 26 | N/A | United States |
| 6 | JPRN-UMIN000022023 | 2016/05/10 | 10/05/2016 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease. -to evaluation by change of intestinal bacterial flora- | Parkinson diseaseChronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollmen | Dokkyo Medical University | NULL | Complete: follow-up complete | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan | |
| 7 | JPRN-UMIN000022022 | 2016/05/10 | 10/05/2016 | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease - A randomized controlled study comparing lubiprostone and magnesium oxide for treatment of chronic constipation in patients with Parkinson disease | Parkinson diseaseChronic constipation | Study drug group: A 12-week administration of lubiprostone 24 microrgrum (adjustable) twice daily after switching from magnesium oxide Control group: Continuous administration of magnesium oxide at the same dosage regimen as before the enrollment | Dokkyo Medical University | NULL | Complete: follow-up complete | 20years-old | 90years-old | Male and Female | 64 | Not selected | Japan |
| 8 | NCT02775591 (ClinicalTrials.gov) | April 2016 | 9/5/2016 | Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms | Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial | Parkinson Disease;Dyspepsia | Drug: DA-9701;Drug: DA-9701 placebo | Seoul National University Hospital | Samsung Medical Center;Korea University Guro Hospital;Hanyang University;Seoul Veterans Hospital;SMG-SNU Boramae Medical Center | Completed | 50 Years | 80 Years | All | 147 | Phase 4 | Korea, Republic of |
| 9 | NCT02572713 (ClinicalTrials.gov) | October 2015 | 7/10/2015 | Systemic Synuclein Sampling Study (S4) | Systemic Synuclein Sampling Study (S4) | Parkinson's Disease | Procedure: Biofluid samplings;Procedure: Tissue samplings;Drug: DaTSCAN™ | Michael J. Fox Foundation for Parkinson's Research | Indiana University;University of Iowa;Banner Health;Paracelsus Elena Klinik | Completed | 40 Years | N/A | All | 80 | N/A | United States;Canada |
| 10 | JPRN-UMIN000006521 | 2011/10/01 | 11/10/2011 | Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease | Switch trial from Pramipexole IR (Bi-sifrol) to Pramipexole ER (Mirapex LA) in patients with Parkinson's disease - Switch trial from IR to ER of Pramipexole | Parkinson's disease | Rapid switch of Pramipexole ER (once in a day) which is same dose as IR. The period of administration is 8 weeks. | Department of Neurology, Juntendo University | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan |
| 11 | ChiCTR-TRC-07000027 | 2007-11-01 | 2007-11-09 | A randomized controlled clinical study of Pramipexole for Parkinson's disease | A randomized controlled clinical study of Pramipexole for Parkinson's disease | Primary Parkinson's disease | Group 1:Artane oral 1-2mg, tid,+ Mirapexin, 0.25 mg/d at beginning, and add to 1.0 mg/d at the end of the second week; the dose will be added from the second weekend to the eighth week to 4. 5 mg/d(1.5 mg, tid); maintain the dose during 12 weeks and reduce the dose during 1-4weeks;Group 3:Artane oral 1-2mg, tid + Madopar, 62.5~500 mg, 2~4 times a day depends on the serious of disease + Mirapexin, the dose is same as group 1;Group 2:Artane oral 1-2mg, tid+ Benserazide-Levodopa (Madopar), oral 62.5~500 mg, 2~4 times a day depends on the serious of the disease; | First Affiliated Hospital of Xinjiang Medical University | NULL | Completed | 30 | 80 | Both | Group 1:45;Group 3:45;Group 2:45; | China | |
| 12 | NCT00070941 (ClinicalTrials.gov) | July 2003 | 9/10/2003 | SAM-e for the Treatment of Depression in Patients With Parkinson's Disease | SAM-e Treatment of Depression in Parkinson's Disease. | Parkinson's Disease;Depression | Drug: SAM-e;Drug: oral escitalopram;Drug: placebo | New York University School of Medicine | National Center for Complementary and Integrative Health (NCCIH);Office of Dietary Supplements (ODS) | Completed | 30 Years | 80 Years | All | 29 | Phase 2/Phase 3 | United States |